Mirtazapina Almus (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising 5‑HT2 and 5‑HT3 receptors while stimulating 5‑HT1A receptors. This dual action boosts serotonergic and noradrenergic neurotransmission, contributing to mood improvement.

The appropriate dose is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Physicians typically start with a low dose and may adjust it gradually; exact dosing instructions should always follow the prescriber’s order.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Mirtazapine differs from selective serotonin reuptake inhibitors (SSRIs) by its noradrenergic and specific serotonergic (NaSSA) mechanism, which often results in stronger sedative and appetite‑stimulating effects. While SSRIs are generally activating, mirtazapine may be preferred when insomnia or weight loss are prominent concerns.

Store the product at ambient temperature, preferably below 25 °C, in the original packaging to protect it from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

Mirtazapina Almus is taken orally, usually once daily in the evening because of its sedative effect. It may be swallowed with or without food; however, taking it with a light snack can reduce occasional stomach upset.

Serious risks include agranulocytosis or severe neutropenia, hepatic dysfunction, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, especially during the initial weeks of therapy.

Mirtazapina Almus is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently receiving monoamine oxidase inhibitors (MAOIs) or who have taken an MAOI within the past 14 days. Caution is also advised in severe hepatic impairment.